FDA Clears AI-Powered Cardiovascular Ultrasound System from Siemens Healthineers
Offering a variety of AI features for streamlined workflow and enhanced visualization, the Acuson Origin ultrasound system also features the newly FDA-cleared AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Acuson Origin cardiovascular ultrasound system and the accompanying AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter.
The Acuson Origin system reportedly bolsters workflow efficiency for transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) with over 5,600 artificial intelligence (AI) automated measurements, according to Siemens Healthineers, the manufacturer of the device.
The Acuson Origin ultrasound system reportedly bolsters workflow efficiency for transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) with over 5,600 artificial intelligence (AI ) automated measurements, according to Siemens Healthineers, the manufacturer of the device. (Image courtesy of Siemens Healthineers.)
AI Assist, one of the new TTE features for the Acuson Origin, provides automated positioning of color and spectral Doppler regions of interest. Offering real-time cardiac view recognition, Siemens Healthineers said the 4D HeartAI feature has a 98 percent accuracy for the identification and alignment of multiplanar reconstruction (MPR).
“With its advanced AI features and potential to enhance diagnostic accuracy as well as patient care, the Acuson Origin is positioned to reshape health care’s approach to cardiovascular imaging,” noted David Zollinger, the head of cardiovascular ultrasound at Siemens Healthineers.
Providing advanced imaging for complex heart procedures, Siemens Healthineers noted the AcuNav Lumos catheter promotes enhanced accuracy of anatomical assessments with MPR biplane imaging. The device’s real-time 4D color Doppler capabilities also facilitate improved leak detection, according to Siemens Healthineers.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
